Immunological mechanisms of allergen-specific immunotherapy

被引:605
作者
Larche, Mark
Akdis, Cezmi A.
Valenta, Rudolf
机构
[1] McMaster Univ, Dept Med, Div Clin Immunol & Allergy, Hamilton, ON L8N 3Z5, Canada
[2] Univ London Imperial Coll Sci Technol & Med, MRC & Asthma UK Ctr Allerg Mechanisms Asthma, Dept Allergy & Clin Immunol, Natl Heart & Lung Inst,Fac Med, London SW7 2AZ, England
[3] Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland
[4] Med Univ Vienna, Div Immunopathol, Dept Pathophysiol, Ctr Physiol & Pathophysiol, A-1090 Vienna, Austria
基金
英国医学研究理事会; 加拿大创新基金会; 奥地利科学基金会;
关键词
D O I
10.1038/nri1934
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Allergen-specific immunotherapy has been carried out for almost a century and remains one of the few antigen-specific treatments for inflammatory diseases. The mechanisms by which allergen-specific immunotherapy exerts its effects include the modulation of both T-cell and B-cell responses to allergen. There is a strong rationale for improving the efficacy of allergen-specific immunotherapy by reducing the incidence and severity of adverse reactions mediated by IgE. Approaches to address this problem include the use of modified allergens, novel adjuvants and alternative routes of administration. This article reviews the development of allergen-specific immunotherapy, our current understanding of its mechanisms of action and its future prospects.
引用
收藏
页码:761 / 771
页数:11
相关论文
共 148 条
[41]  
Feinberg SM, 1940, J AMER MED ASSOC, V115, P23
[42]   Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: Results of a phase I trial [J].
Fellrath, JM ;
Kettner, A ;
Dufour, N ;
Frigerio, C ;
Schneeberger, D ;
Leimgruber, A ;
Corradin, G ;
Spertini, F .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (04) :854-861
[43]  
Flicker S, 2002, EUR J IMMUNOL, V32, P2156, DOI 10.1002/1521-4141(200208)32:8<2156::AID-IMMU2156>3.0.CO
[44]  
2-A
[45]   Allergic disease and sensitization in Steiner school children [J].
Flöistrup, H ;
Swartz, J ;
Bergström, A ;
Alm, JS ;
Scheynius, A ;
van Hage, M ;
Waser, M ;
Braun-Fahrländer, C ;
Schram-Bijkerk, D ;
Huber, M ;
Zutavern, A ;
von Mutius, E ;
Üblagger, E ;
Riedler, J ;
Michaels, KB ;
Pershagen, G .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (01) :59-66
[46]   Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination [J].
Focke, M ;
Mahler, V ;
Ball, T ;
Sperr, WR ;
Majlesi, Y ;
Valent, P ;
Kraft, D ;
Valenta, R .
FASEB JOURNAL, 2001, 15 (09) :2042-+
[47]   Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy [J].
Francis, JN ;
Till, SJ ;
Durham, SR .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (06) :1255-1261
[48]  
Freeman J, 1911, LANCET, V2, P814
[49]   Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1 [J].
Gafvelin, G ;
Thunberg, S ;
Kronqvist, M ;
Grönlund, H ;
Grönneberg, R ;
Troye-Blomberg, M ;
Akdis, M ;
Fiebig, H ;
Purohit, A ;
Horak, F ;
Reisinger, J ;
Niederberger, V ;
Akdis, CA ;
Cromwell, O ;
Pauli, G ;
Valenta, R ;
van Hage, M .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2005, 138 (01) :59-66
[50]   X-ray and NMR structure of Bet v 1, the origin of birch pollen allergy [J].
Gajhede, M ;
Osmark, P ;
Poulsen, FM ;
Ipsen, H ;
Larsen, JN ;
vanNeerven, RJJ ;
Schou, C ;
Lowenstein, H ;
Spangfort, MD .
NATURE STRUCTURAL BIOLOGY, 1996, 3 (12) :1040-1045